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Radioimmunologic method for detection of antitubular base-
ment membrane antibodies. A radioimmunoassay for detection of
antitubular basement membrane (TBM) antibodies was set up us-
ing a human TBM antigen (mol wt, 70,000 daltons), purified after
collagenase treatment of the insoluble membrane by preparative
polyacrylamide electrophoresis, and labeled with iodine 125.
Free labeled antigens were separated from those bound to immu-
noglobulins by a 20% polyethylene glycol (mol wt, 6,000 daltons)
solution. In the presence of normal human or Brown Norway rat
sera, less than 10% of the labeled antigens were precipitated. In
the presence of sera or of kidney eluates from rats immunized
with human TBM, the precipitation of the labeled TBM antigens
reached 73%, but in the presence of sera from two patients pre-
senting with an interstitial nephritis and linear deposits along the
TBM only, up to 47% of the same antigens were precipitated. In
these two cases, the anti-TBM antibodies were mainly directed
against the heteropolysaccharide-containing glycopeptides iso-
lated from TBM, that is, against the noncollagenous poly-
peptides of the TBM antigens. Anti-TBM antibodies were sought
in the sera of 52 normal blood donors and of 11 patients present-
ing with glomerulonephritis and linear deposits of immunoglobu-
lins. The average percentage (± I SD) of labeled TBM antigens
precipitated in the serum of normal blood donors was 7.1 1.2.
Of the patients presenting with glomerulonephritis and linear de-
posits along the GBM, 9 out of 11 exhibited anti-TBM antibodies
by radioimmunoassay; among these 9 patients, 8 also displayed
linear deposits of IgG along the TBM. Absorption of anti-TBM
and anti-GBM antibodies with particulate TBM or GBM, with
both types of glycopeptides isolated from GBM or TBM, in-
dicated that the anti-TBM antibodies were directed against the
noncollagenous polypeptides of TBM but that the anti-GBM
antibodies mainly reacted with the collagenous polypeptides of
TBM and GBM. Finally, it was found that the sera of 2 patients
out of 15 presenting with lupus nephritis contained a significant
anti-TBM-binding activity, mainly directed against the non-
collagenous material of TBM.
Méthode radioimmunologique de detection des anticorps anti-
membrane basale tubulaire. Une méthode radioimmunologique
permettant Ia detection des anticorps antimembrane basale tubu-
laire (TMB) a été développée, en utilisant des antigenes solubles
purifies aprés digestion a Ia collagenase de TMB humaines, par
électrophorèse preparative sur gel de polyacrylarnide. Ces anti-
genes, dont le poids moléculaire est 70.000 daltons, ont été mar-
qués a l'iode 125. Les antigènes membranaires libres, marques
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au radio-iode, sont separés de ceux fixes aux anticorps anti-TMB
au moyen dune solution de polyethylene glycol (poids molecu-
laire 6.000 daltons) a 20%. En presence de serums humains ou
de rats Brown Norway normaux, moms de 10% des antigènes
radioactifs sont precipites. En presence des serums ou des e-
luats de reins de rats immunisés avec des TMB humaines, Ia
precipitation des antigènes marques atteint 73%; en presence
des serums de deux patients atteints de nephropathie tubulo-
interstitielle avec depots lineaires exclusivement tubulaires, 47%
des mêmes antigènes sont precipites par le polyethylene glycol a
20%. Chez ces deux patients, tes anticorps anti-TMB sont dirigés
préférentiellement contre les glycopeptides contenant les
chaines heteropolysaccharidiques isolés des TMB, c'est-à-dire
contre les polypeptides de nature noncollagéne des antigenes
tubulaires. Les anticorps anti-TMB ont ete recherchés dans le
serum de 52 sujets normaux, donneurs de sang, et de II patients
presentant une glomerulonephrite avec depOts lineaires
d'immunoglobulines. Le pourcentage moyen de precipitation
(± I SD) des antigènes tubulaires marques obtenu dans les se-
rums normaux est 7.1 1.2. Neuf des 11 patients atteints de
glomérulonephrite avec depOts linéaires le long des 0MB pos-
sèdent des anticorps anti-TMB décelables par dosage radio-
immunologique; parmi ces 9 patients, 8 présentent egalement
des depOts linéaires d'immunoglobulines situés le long des
TMB. Let anticorps anti-TMB et les anticorps anti-GMB ont eté
absorbés sur let TMB ou les 0MB insolubles, et sur let deux
types de glycopeptides isolés des GMB ou des TMB. Ces ex-
périences ont permis de démontrer que les anticorps anti-TMB
réagissent, de manière préférentielle, avec les polypeptides de
nature noncollagene des TMB, tandis que les anticorps anti-
GMB sont dirigés contre les polypeptides de nature collagène
des TMB et des GMB. Enfin, Ia recherche d'anticorps anti-TMB
dans le serum de 15 patients presentant une nephropathie lu-
pique s'est averee positive chez 2 patients, ces anticorps étant
egalement diriges contre le materiel noncollagéne des TMB.
it is generally admitted that antiglomerular base-
ment membrane (anti-GBM) antibodies are involved
in the pathogenesis of some instances of human and
experimental glomerulonephritis (GN) [1—3]. Until
recently, little consideration was given to the possi-
bility that similar immunologic mechanisms might
directly inflict damage on the renal tubules and in-
terstitial tissue. In the past several years, experi-
mental interstitial nephritides have been produced
by the immunization of guinea pigs [4] or certain
strains of rats [5, 6] with appropriate renal tubular
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basement membrane (TBM) preparations. Inter-
stitial nephritides associated with anti-TMB anti-
bodies have been subsequently described in some
patients presenting with Goodpasture's syndrome,
a rapidly progressive glomerulonephritis [71, or an
immune-complex glomerular disease [8, 9]. In addi-
tion, anti-IBM antibodies have been detected in the
serum of a patient presenting with a methicillin-as-
sociated interstitial nephritis [101 and in the sera of
patients with a renal allograft [11—131.
In these cases, the presence of anti-TBM anti-
bodies was demonstrated by immunofluorescence
microscopy performed directly on the diseased kid-
ney or after transfer of circulating or eluted anti-
bodies onto normal kidney slices. The existence of
anti-IBM antibodies was then confirmed by the
presence of linear deposits of IgG along the IBM
[4—131. Radioimmunologic methods have been re-
cently described for the detection of circulating or
eluted anti-GBM antibodies [14—16]. Our technique,
which has been described in detail [14], is based on
the fact that most of the immunoglobulin molecules
are precipitated by a 20% polyethylene glycol
(PEG) solution, whereas the GBM antigens remain
soluble at this PEG concentration. In the present
study, a direct binding test, based on the same prin-
ciple, is described for the detection of anti-IBM
antibodies. Since the TBM isolated from human
kidneys is associated with interstitial collagen fibers
[17], IBM antigens have been purified after collage-
nase treatment of the initially insoluble membranes.
Since the selected TBM antigens remain soluble in a
20% PEG solution, this solution has been used to
separate free IBM antigens from those bound to
immunoglobulins. The specificity of anti-IBM anti-
bodies for human IBM antigens has also been in-
vestigated. Finally, anti-IBM antibodies were
sought in the serum of 52 normal blood donors and
of 28 patients with various nephropathies.
Methods
lected for radioimmunologic studies (Fig. 1). Neu-
tral sugars, hexosamines, and sialic acid were mea-
sured by previously described techniques [l7j;
amino-acid composition was determined in a Beck-
man model Unichrom amino-acid analyzer (Beck-
man Instruments, Inc. Fullerton, Calif.) [191. The
protein content was measured by the method of
Lowry et al., with bovine serum albumin as a stan-
dard [201. Human GBM antigens were prepared as
previously described [191. The glycopeptides
containing either the disaccharide or the hetero-
polysaccharide chains were isolated, after enzymat-
ic digestion of IBM or GBM with pronase and
collagenase, by gel filtration, ion exchange chro-
matography, and preparative paper electrophoresis
[18]. The glycopeptide concentration was measured
by the ninhydrin reaction with leucine as a standard
[211.
Clq was purified by the method of Yonemasu and
Stroud [22]. Human type 1 procollagen was a gift
from Prof. C.M. Lapière, University of Liege, and
highly polymerized calf thymus DNA was a gift
from Prof. E. Fredericq (University of Liege).
Denatured DNA was prepared by heating native
x
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Buffer. All serum dilutions or PEG solutions were
made in borate buffer (ionic strength, 0.1; pH, 8.3-
8.5).
Antigens. TBM were isolated from normal human
kidneys obtained from autopsies and were solubi-
lized by collagenase digestion (collagenase from
Clostridium histolyticum, type Ill, fraction A, 460
U/mg, Sigma Chemical Co.), as previously de-
scribed [18]. IBM polypeptides were purified from
the solubilized material by preparative polyacryl-
amide electrophoresis [19]. A soluble TBM fraction
with an average mol wt of 70,000 daltons was se-
Gel slice number
Fig. 1. Acrylamide disc gel electrophoresis in dodecylsulfate of
labeled and unlabeled TBM antigens. Before running, samples
were incubated with 4% sodium dodecylsulfate and 0.1 M mer-
captoethanol for 1 hour at 60° C; 7.5% gels were used, and the
proteins were stained with Coomassie blue. The gels were also
sliced, and the radioactivity of gel slices (about 0.5 cm in thick-
ness) was counted in a double channel Picker nuclear spectrome-
ter (Picker Corp., Cleveland, Oh.). Molecular weight of TBM
antigens was calculated by comparison with the relative mobility
of albumin standards [14]. The arrows denote the dye front.
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DNA (0.5 mg/mi in phosphate-buffered saline; pH,
7.0) at 100° C for 10 mm, followed by immediate
cooling in an ice bath. DNA was fractionated on
methylated albumin kieselguhr columns, according
to Sueoka and Cheng [23], to separate double-
stranded from single-stranded DNA. lodination of
DNA was carried out according to the method of
Commerford [24].
Preparation of the labeled TBM and GBM anti-
gen solutions. One hundred micrograms of the puri-
fied TBM antigens were labeled with iodine 125 by
the method of McConahey and Dixon [25]. Free io-
dine, however, was separated from protein-bound
iodine by gel filtration on Sephadex G-50 columns.
The column was eluted using the borate buffer con-
taining 1% albumin. After elution, the labeled TBM
antigen solution was divided into 0.1-ml samples
and stored at —20° C. The TBM antigens exhibited
a specific activity of about 2 /LCi//Lg. Before each
testing, they were diluted with the borate buffer to a
protein concentration of 0.1 /Lg/ml. The TBM anti-
gens after iodination and the uniodinated antigens
exhibited the same molecular weight as that demon-
strated by acrylamide disc gel electrophoresis in
dodecylsulfate (Fig. 1), thus indicating that the ini-
tial TBM antigen and not a minor contaminant was
being measured in the radioimmunoassay. The la-
beled GBM antigen solution was prepared as pre-
viously described [14].
Antibodies. Rat antihuman TBM antibodies were
obtained by s.c. injection of Brown Norway (BN)
rats with 4 mg of. lyophilized human TBM contained
in 0.5 ml of saline solution and mixed with equal
volumes of complete Freund's adjuvent and alu-
mine hydroxide. The specificity of anti-TBM anti-
bodies was tested by immunofluorescent micros-
copy performed on normal rat kidney slices, ac-
cording to the method of Unanue and Dixon [3].
About 1 month after immunization, all the rats
showed linear fluorescence for Ig along the TBM of
about 70% of cortical tubules, but no linear deposits
were obvious along the GBM. BN rats were also
injected with 4 mg of the TBM antigens purified af-
ter collagenase treatment of the starting insoluble
membranes. The immunogen was dissolved in 0.5
ml of saline solution and mixed with equal volumes
of complete Freund' s adjuvent and alumine hydrox-
ide. The inoculum (1.5 ml) was divided between all
four footpads and several intradermal sites on the
back. After 1 month, all the rats exhibited linear cir-
cumferential deposits of Ig along the TBM of about
70% of their cortical tubules (Fig. 2); no linear de-
posits were obvious along the GBM. An interstitial
infiltration of mononuclear cells was observed on
day 30 and thereafter. Occasional multinucleated gi-
ant cells were seen. At that time, all 20 BN rats used
for renal function studies appeared healthy. None
developed glycosuria and proteinuria. These latter
observations indicate that immunization with the
soluble TBM antigens induces a mild tubulo-
interstitial nephritis, comparable to that observed
when particulate TBM are used as an immunogen
[6].
Human anti-TBM antibodies were obtained from
sera of two patients presenting with an interstitial
nephritis and linear deposits of IgG along the TBM.
In both cases, the linear deposits along the TBM
appeared secondarily to an immune complex gb-
merular disease associated with a nephrotic syn-
drome. The first renal biopsies showed massive,
granular, immune-complex deposits containing
IgG, C3, and 1gM in the subepithelial part of the
GBM. No deposits were seen along the TBM.
About 6 months after the onset of the nephrotic syn-
drome, anti-TBM antibodies were detectable in the
sera samples of both patients by indirect immuno-
fluorescence. The second renal biopsies revealed
interstitial nephritides, and linear deposits of IgG
and C3 along the TBM of cortical tubules were ob-
served by immunofluorescent microscopy. Both pa-
tients developed a Fanconi's syndrome. The serum
sample of one of these two patients was provided by
Drs. Levy and Habib (Hôpital Necker, Paris).
Rat and human IgG were prepared by ion ex-
change chromatography on DEAE-cellulose [26].
Immunoglobulins were eluted from the kidneys of
rats immunized with human TBM, with 0.02 M cit-
rate buffer (pH, 2.8) according to the method of
Lambert and Dixon [27]; IgG concentration in the
eluate was determined by quantitative radial immu-
nodiffusion [281. Rabbit antihuman GBM, antiwhole
human serum and anti-Clq antibodies were ob-
tained by immunization of rabbits with the purified
antigens mixed with complete Freund's adjuvent.
Rabbit antitype IV collagen antibodies were a gift
from Dr. N.A. Kefalides, Department of Medicine
and Biochemistry, University of Pennsylvania,
Philadelphia, Penn., and human anti-DNA anti-
bodies were a gift from Dr. G. Fournié, Department
of Nephrobogy, Toulouse, France.
Radioimmunologic procedure. The solubility of
'251TBM antigens (Ag) was studied in the presence
of various PEG solutions. PEG, with an average
mol wt of 6,000 daltons (Siegfried, Zofingen, Switz-
erland), was dissolved in borate buffer (ionic
strength, 0.1; pH, 8.3) at concentrations from 10%
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Fig. 2. Section of kidney from a Brown Norway rat immunized with thehuman TBM antigens purified after collagenase treatment of the
starting insoluble membrane. Continuous linear, circumferential deposits of Ig are seen along the tubular basement membranes. No
linear deposits of Ig are observed along the GMB (fluorescein-isothiocyanate-conjugated rabbit antirat Ig; original magnification, x240).
to 40%; 10 ng of the labeled TBM antigens, con-
tained in 0.1 ml of the borate buffer, were mixed with
0.4 ml of 1/20 normal human serum (NHS) or nor
mal rat serum (NRS) and then mixed further with
0.5 ml of the various PEG solutions. This mixture
was left at 4° C for 12 hours, then centrifuged at x
I ,500g for 20 mm. The supernatant was discarded
and the precipitate washed twice with the PEG so-
lution at the final concentration used in the mixture.
The percentage of '251-TBM Ag precipitated was
calculated after radioactivity-counting in a double-
channel Picker Nuclear Spectrometer, using as a
100% value the radioactivity of '251-TBM Ag precip-
itated with 20% trichloroacetic acid. Anti-TBM
antibodies (Ab) were titrated as follows: 0.1 ml of
1251-TBM Ag solution was mixed with 0.4 ml of test-
ed serum serially diluted in 1/20 NEtS or NRS, then
left at 37° C for 1 hour; 0.5 ml of 40% PEG was add-
ed, and the samples were washed and counted as
for solubility studies, after an overnight incubation
at 40 C. Anti-TBM IgG Ab were titrated by the
same procedure, but a starting IgG solution of 100
p.glml in NHS or NRS was used; in this case, con-
trol experiments were performed with similar con-
centration of normal IgG in NHS or NRS. Before
testing, all sera were heated for 30 mm at 56° C.
Reproducibility and sensitivity of the radioimmu-
noassay. The accuracy of measurement of anti-
TBM antibodies was evaluated by calculating the
coefficient of variation (CV) of results of duplicate
determinations around their means, using Snede-
cor's formula [291. The sensitivity of the radioim-
munoassay was determined by correlating the anti-
IBM antibody titers obtained by this technique
with those obtained by indirect immuno-
fluorescence. Rat antihuman IBM antibodies and
anti-TBM antibodies found in seven sera samples of
two patients with interstitial nephritides and tubular
linear deposits were titrated by the two methods.
Selection of subjects. Anti-TBM antibodies were
sought in the sera samples of 52 normal blood do-
nors and of 28 patients with various nephropathies.
The 2 patients presenting with a typical interstitial
nephritis associated with linear deposits along the
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TBM have been mentioned above (see Antibodies).
Eleven patients exhibited a rapidly progressive GN
with linear deposits of IgG and C3 along the GBM; 8
patients out of II also exhibited linear staining for
IgG and C3 along the TBM. The 15 remaining pa-
tients presented with lupus nephritis: 8 exhibited
granular deposits of immunoglobulins, and usually
C3, on the TBM and the peritubular capillaries, and
7 exhibited no renal extraglomerutar immunoglobu-
un deposits.
Results
Carbohydrate and amino acid composition of the
TBM antigens used for the immunologic studies.
The amino acid composition of the TBM antigens
purified by preparative polyacrylamide elec-
trophoresis is given in Table 1. They contained less
3-OH proline, 4-OH proline, glycine, and hydroxy-
lysine residues than the GBM antigens did, Con-
versely, they contained more lysine, aspartic acid,
and glutamic acid residues than the GBM antigens
did.
The carbohydrate composition of the TBM anti-
gens purified by preparative polyacrylamide elec-
trophoresis is given in Table 2. Although the TBM
antigens contained the same carbohydrates as the
GBM antigens, a lower proportion of glucose and
galactose was found, thus indicating a decrease in
their disaccharide unit content. The carbohydrate
and amino acid composition of the tested disaccha-
ride-containing glycopeptides, purified from TBM
or GBM insoluble material, is given in Table 3.
It should be stressed that these glycopeptides con-
tained glucose, galactose, and hydroxylysine in
equimolecular amounts.
The carbohydrate and amino acid composition of
the tested heteropolysaccharide-containing glyco-
peptides, purified from TBM or GBM insoluble ma-
terial, is given in Table 4. Aspartic acid, threonine,
serine, glutamic acid, proline, glycine, and alanine
were the most abundant amino acids of these glyco-
peptides. No hydroxylysine or glucose residues
were found. The heteropolysaccharide chain was
formed of fucose, hexosamines, mannose, galac-
tose, and sialic acid, The heteropolysaccharide
units of the TBM glycopeptides contained fewer
sialic acid residues than did the heteropolysacchar-
ide units of the GBM glycopeptides.
Detection of anti-TBM antibodies in the sera and
kidney eluates from Brown Norway rats. The solu-
bility of labeled TBM antigens was studied in the
presence of the various PEG concentrations. The
addition of 0.5 ml of 40% PEG to 10 ng of labeled
Table 1. Amino acid composition of GBM and TBM antigens
used for the immunological studies
Amino acid
GBM antigens8 TBM antigens
residue/I .000 ams'no acid residues
Cysteic acid 23.6 39.2
3-Hydroxyproline 10.3 3.5
4-Hydroxyproline 65.1 29.6
Aspartic acid 74.0 101.2
Threonine 38.2 42.0
Serine 42.3 69.8
Glutamicacid 90.5 121.1
Proline 64.0 51.0
Glycine 232.2 156.3
Alaiine 50.6 71.1
Valine 41.3 44.2
Methionine 16.9 11.5
Isoleucine 30.1 30.8
Leucine 75.9 56.2
Tyrosine 16.4 20.7
Phenylalanine 26.6 26.4
Hydroxylysine 26.7 7.1
Lysine 20.2 31.2
Histidine 13.0 25.4
Arginine 42.1 61.7
a GBM antigens purified by affinity chromatography and pre-
parative polyacrylamide electrophoresis [19].
Table 2. Carbohydrate composition of GBM and TBM antigens
used for the immunological studies
Monosaccharide
GBM antigensa IBM antigens
mg/l00 mg of protein
Glucose
Galactose
Mannose
Fucose
Hexosamines
Sialic acid
3.05
3.48
0.89
0.41
1.45
1.04
0.74
1.99
0.71
0.29
3.24
0.85
a GBM antigens purified by affinity chromatography and pre-
parative polyacrylamide electrophoresis [19].
Table 3. Carbohydrate and amino acid composition of the
disaccharide-containing glycopeptides used for the
immunological studies
Componenta
GBM glycopeptide TBM glycopeptide
mole/mole glucose
Glucose 1.0 1.0
Galactose 1.0 1.02
Hydroxylysine 0.98 1.01
Glycine 2.02 1.91
Aspartic acid 1.01 1.32
Glutamic acid 0.89 0.99
a In addition to these amino acids, smaller amounts of hy-
droxyproline, proline, and serine were also present.
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Table 4. Carbohydrate and amino acid composition of the
heteropolysaccharide-containing glycopeptides used for the
immunological studies
Component8
GBM glycopeptide IBM glycopeptide
mole/mole fucose
Fucose 1.0 1.0
Hexosamines 5.3 4.6
Galactose 3.9 4.9
Mannose 3.5 3.4
Sialic acid 4.5 1.6
Asparticacid 1.5 1.4
Threonine 0.6 0.5
Senne 0.8 0.8
Glutamic acid 0.7 1.1
Proline 0.9 0.7
Glycine 1.2 2.1
Alanine 0.8 0.4
Valine 0.4 0.5
a In addition to these amino acids, smaller amounts of leucine,
isoleucine, and lysine were also present.
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Fig. 4. Titration of antibodies to human TBM by precipitation
of immunoglobulin-bound antigens with 20% PEG solution.
Titration curves obtained either with whole rat antiserum(• •) or with IgG purified from the serum of a patient
presenting with an interstitial nephritis and linear deposits
(0 0) are represented.
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Fig. 3. Solubilisy of labeled TBM Ag at various PEG concentra-
rions, in presence of NRS /120 (0 0), of NHS 1/20(• •), of rat anti-TBM lgG solution diluted 20 times
(A A), and of the serum, diluted 20 times, of a patient
presenting with an interstitial nephritis and linear deposits along
the TBM (
TBM Ag contained in 0.5 ml of NRS 1/20 precipi-
tated less than 10% of the radioactive antigens.
Thus, the TBM antigens remain quite soluble in a
20% PEG solution, which precipitates all the Ig
molecules [30]. In the presence of rat antihuman
TBM IgG antibodies, the precipitation of the la-
beled TBM antigens reached 73% (Fig. 3). It should
be stressed that these sera samples did not signifi-
cantly precipitate the labeled GBM antigens.
An example of titration curve obtained with
whole rat antiserum is given in Fig. 4. In this case,
the anti-IBM antibody titer (inverse of the serum
dilution at which 10% of the TBM antigens are pre-
cipitated) averaged 2. l0-. Similar titration curves
have been obtained using either purified rat anti-
IBM IgG or immunoglobulins eluted from the kid-
neys of rats immunized with human IBM.
Detection of anti-TBM antibodies in the sera
samples of two patients presenting with an inter-
stitial nephritis and linear deposits along the TBM.
In the presence of the 20% PEG solution, the per-
centage of precipitation of labeled IBM Ag in NHS
1/20 was lower than 10%. In the presence of a simi-
larly diluted sera sample of a patient presenting with
an interstitial nephritis and linear deposits along the
TBM, however, 47% of the same antigens were pre-
cipitated. No significant precipitation of the labeled
GBM antigens was obtained in the same serum
sample at a different time with identical experiment
conditions.
Titration of human antibodies to TBM antigens
was performed with the 20% PEG solution. An ex-
ample of titration curve obtained with the purified
IgG is given in Fig. 4. In this case, the anti-TBM
antibody titer averaged 2.l0—.
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Detection of anti-TBM and anti-GBM antibodies
in human nephropathies: Correlations with the im-
munofluorescent microscopic data. The percentage
of precipitation of labeled TBM Ag in the serum of
52 normal blood donors was 7.1 1.2. (mean val-
ue 1 SD). It was considered that the sera of those
patients with at least 9.6% of labeled TBM Ag pre-
cipitated had significant anti-IBM activities. The
results of anti-IBM antibody titers in the sera of 28
patients presenting with several nephropathies are
given in Fig. 5. It should be stressed that (a) the 2
patients presenting with an interstitial nephritis and
linear deposits along the IBM exhibited the highest
anti-IBM antibody titers; (b) the 8 patients present-
ing with GN and linear deposits along the GBM and
IBM exhibited significant, albeit lower, anti-TBM
activity in their serum; (c) 2 patients out of 3 pre-
senting with GN and linear deposits along the GBM
only, exhibited negative results; the serum sample
of the 3rd patient had a very low anti-IBM activity
(0.4%); (d) only 2 patients out of 15 presenting with
a systemic lupus nephritis exhibited anti-IBM ac-
tivity in their sera samples. In 5 of these "positive"
patients, IgG fractions purified from sera samples
were shown to contain a significant IBM binding
activity.
After correction for nonspecific precipitation of
.
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the labeled GBM Ag, as obtained from a pool of 92
normal blood donor's sera [14], the percentage of
labeled GBM Ag precipitated in the sera of 52 nor-
mal blood donors was 0.5 4.6% (mean value I
SD). It has been considered that patients with at
least 9.8% precipitation of labeled GBM Ag exhib-
ited a significant anti-GBM activity in their sera
samples. The results of anti-GBM antibody level
determinations in the sera samples of the afore-
mentioned global group of 28 patients are given in
Fig. 5. It should be stressed that (a) the 2 patients
presenting with an interstitial nephritis and linear
deposits along the IBM exhibited negative results;
(b) all patients presenting with GN and linear depos-
its along the GBM had high anti-GBM antibody ti-
ters; (c) no patient presenting with lupus nephritis
exhibited significant anti-GBM activity.
In those patients presenting with GN and linear
deposits along the GBM and TBM, no significant
difference could be detected between anti-GBM and
anti-IBM reactivities.
Specificity of human and rat anti-TBM antibodies
for basement membrane antigens: (1) SpecficiIy of
the anti-TBM antibodies detected in interstitial
nephriiis with linear TBM deposits. To assess the
specificity of the radioimmunoassay, rabbit antitype
IV collagen, antiwhole human serum or anti-Clq
antibodies were incubated with the labeled IBM
antigens. No significant precipitation was observed.
Inhibition experiments were then performed with
either the anti-IBM antibodies eluted from kidneys
of rats immunized with IBM or the anti-IBM anti-
bodies detected in the sera samples of the two pa-
tients presenting with an interstitial nephritis and
linear deposits along the IBM. Increasing amounts
of unlabeled IBM antigens, GBM antigens, Clq,
and procollagen were incubated with a solution of
anti-IBM antibodies binding specifically 20% of the
labeled IBM polypeptides. The results are given in
Fig. 6. One microgram of unlabeled TBM antigens
strongly inhibited the binding of 10 ng of labeled an-
tigens with anti-TBM antibodies, but similar
amounts of GBM antigens, Clq, and procollagen
only slightly reduced the specific precipitation. To
control the specificity of the anti-TBM antibodies,
immunoabsorption experiments were performed.
Eluates from rats immunized either with the in-
soluble TBM or with the soluble IBM antigens
were pooled separately, and the lgG were concen-
trated to 500 g!ml. One-hundred-microliter ali-
quots from each pool were mixed with suspensions
of 100 tl of particulate human GBM or IBM con-
taining 2 mg of protein. Absorption was allowed to
•0
0.
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0
a
I.-
0)
0)
.0
0)
Interstitial
nephritis
with
linear
TBM
deposits
GN with
linear
GBM and
TBM
deposits
GN with
linear
GBM
deposits
Lupus
nephritis
with
granular
deposits
Lupus
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any deposits
Fig. 5. Anti-TBM and anti-GBM antibody levels in sera of pa.
tients presenting with various nephropathies. Anti-TBM (•) and
anti-GBM (0) antibodies have been looked for by precipitation
with 20% PEG in the serum of 2 patients presenting with an inter-
stitial nephritis and linear TBM deposits, of 8 patients presenting
with a ON and linear GBM and IBM deposits, of 3 patients pre-
senting with a ON and linear GBM deposits, and of 15 patients
presenting with lupus nephritis. Only patients exhibiting at least
9.6% of radioactive TBM Ag and 9.8% of radioactive GEM Ag
precipitated were considered to present a significant binding of
IBM and GBM antigens, respectively.
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Antigen added,ng
Fig. 6. Inhibition of binding of labeled TBM Ag with anti-TBM
antibodies by various unlabeled antigens. Increasing amounts of
TBM antigens (• •), ofGBM antigens (0 0), of
CIq (A A), and of procollagen (A A) were added
to a solution of human anti-TBM antibodies binding specifically
20% of labeled TBM Ag.
proceed for 1 hour at 370 C and then overnight at
4° C. The mixture was centrifuged at x 2,000g for 30
mm at 4° C, after which the supernatant was tested
for anti-TBM antibodies by radioimmunoassay. The
anti-TBM activity was completely absorbed by par-
ticulate TBM, but remained unchanged alter ab-
sorption with particulate GBM.
In an attempt to further determine the chemical
nature of the TBM-specific antigenic determinants,
increasing amounts of both types of TBM or GBM
glycopeptides were added to a solution of anti-TBM
antibodies eluted from rat kidneys, and binding spe-
cilically 20% of the labeled TBM antigens. One hun-
dred nanograms of the heteropolysaccharide-con-
taming glycopeptide isolated from human TBM in-
hibited 60% of the binding of labeled TBM antigens
with anti-TBM antibodies. Conversely, 100 ng of
the heteropolysaccharide containing glycopeptide
isolated from human GBM or of the disaccharide-
containing glycopeptides purified from TBM and
GBM reduced the specific precipitation by only 2%
to 8% (Fig. 7).
(2) Specificity of the anti-TBM antibodies detect-
ed in GN with linear GBM and TBM deposits. Ra-
dioimmunoassay inhibition experiments and immu-
noabsorption studies were performed using the sera
of five patients presenting with GN and linear de-
posits along the GBM and IBM. For immuno-
Fig. 7. Inhibition of binding of labeled TBM Ag with anti-TBM
antibodies by both types of glvcopeptides isolated from TBM and
GBM. Increasing amounts of heteropolysaccharide-contain.
ing glycopeptides isolated from TBM (• •) or GBM(0 0), of disaccharide-containing glycopeptides isolated
from TBM (A A) or GBM (A A) were added to a
solution of anti-TBM antibodies binding specifically 20% of la-
beled TBM Ag.
absorption, 0.1 ml of the patients' sera samples
binding specifically 20% of labeled TBM or GBM
antigens was mixed with suspensions of 100 l of
insoluble human GBM or TBM containing 2 mg of
protein. Absorption was allowed to proceed for 1
hour at 37° C and then overnight at 40 C. After cen-
trifugation at x2,000g for 30 mm at 4° C, the super-
natants were tested for anti-TBM and anti-GBM
antibodies by radioimmunoassay. Radioimmunoas-
say inhibition studies were done as described
above. The results are given in Table 5. After ab-
sorption with insoluble human IBM, the binding of
anti-TBM antibodies with the labeled TBM antigens
was reduced by more than 90%, but after absorp-
tion with insoluble GBM, this binding was only re-
duced by 18.6%. One microgram of the soluble
TBM Ag or of the heteropolysaccharide-containing
glycopeptide isolated from TBM strongly inhibited
the binding of the labeled TBM antigens with anti-
TBM antibodies. The soluble GBM Ag, the hetero-
polysaccharide-containing glycopeptide isolated
from GBM, or the disaccharide-containing glyco-
peptides purified from GBM and TBM only slightly
reduced the specific binding. Absorption with in-
soluble GBM and TBM, with soluble GBM Ag, or
with the disaccharide-containing glycopeptides iso-
lated from GBM and TBM strongly reduced the
binding of labeled GBM antigens with anti-GBM
antibodies. On the contrary, the soluble TBM anti-
gens or the heteropolysaccharide-containing glyco-
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Table 5. Immunoabsorption and radioimmunoassay inhibition studies on anti-GBM and anti-TBM antibodies from patients presenting
with linear GBM and TBM deposits
Immunoabsorbent Amount
Inhibition of labeled Ag
precipitateda, %
GBM TBM
Insoluble TBM 1mg 59.2 92.1
SolubleTBMAg ltg 13.1 78.6
Heteropolysaccharide-containing glycopeptide (TBM) 1 tg 3.6 61.2
Disaccharide-containing glycopeptide (TBM) 1 g 52.2 5.8
Insoluble GBM 1 mg 89.9 18.6
SolubleGBMAg 1g 81.2 12.7
Heteropolysaccharide-containing glycopeptide (GBM) I g 18.9 4.6
Disaccharide-containing glycopeptide (GBM) 1 g 59.8 6.2
a Determined by radioimmunoassay; averages of the values obtained with five sera.
peptides purified from GBM and TBM reduced the
specific binding by less than 20%.
(3) SpecUlcity of the anti-TBM antibodies detect-
ed in lupus nephritis. Free circulating DNA can be
detected in the sera of patients with systemic lupus
erythematosus [31], and DNA can bind specifically
to the collagenous material of GBM [321. Since the
selected TBM Ag always contains some disaccha-
ride units, the possibility that circulating DNA
could bind to the TBM Ag was tested by precipi-
tation of radiolabeled TBM Ag-DNA complexes
with 20% PEG, in the conditions used for the radio-
immunoassay. Labeled TBM Ag (10 ng) were mixed
for 1 hour at 37° C with 0.4 ml of heat-inactivated
NHS 1/20 or NRS 1/20, and with increasing
amounts (0.1, 1, 10, and 100 j.g) of native or dena-
tured DNA contained in 0.1 ml of 0.15 M sodium
chloride solution; 0.6 ml of 40% PEG was then add-
ed to the mixture. After an overnight incubation at
4° C, the mixture was centrifuged at x 1 ,500g for 20
mm; the supernatant was discarded, and the precip-
itate washed and counted as described above. Con-
trol experiments were performed according to the
same experimental procedure, but 0.1 ml of 0.15 M
sodium chloride solution was added to the mixture
instead of DNA. No significant difference in the
percentage of labeled TBM Ag precipitated was ob-
served between both experimental conditions, thus
indicating that the TBM Ag selected for the immu-
nologic studies did not bind, in vitro, to native or
denatured DNA. The possibility that the labeled
TBM Ag could be bound to DNA-anti-DNA com-
plexes was excluded by the following experiments.
First, the influence of DNA-anti-DNA complexes
on the precipitation of labeled TBM Ag was exam-
ined. To this purpose, antibodies directed against
double-stranded and single-stranded DNA were
used; 0.1 ml of heat inactivated anti-DNA anti-
serum diluted 20 times was incubated overnight at
4° C with 1 p.g of unlabeled DNA contained in 0.1
ml of phosphate-buffered saline (pH, 7.0). One hun-
dred nanograms of labeled TBM Ag contained in 0.1
ml of borate buffer were then added to the mixture.
After an incubation of 1 hour at 37° C, 0.3 ml of 40%
PEG solution was added, and the mixture was fur-
ther incubated overnight at 4° C. The percentage of
1251-TBM Ag precipitated was calculated as for the
standard radioimmunologic procedure. To control
the formation of DNA-anti-DNA complexes, 100 ng
of 125 I-DNA were incubated with 0.1 ml of heat-in-
activated anti-DNA antiserum diluted 20 times, and
the serum 125I-DNA binding activity was deter-
mined by the method of Farr [33]. The results are
shown in Table 6. The percentage of labeled TBM
Ag precipitated was not influenced by the presence
of preformed DNA-anti-DNA complexes.
Second, the sera of the two patients presenting
with lupus nephritis and anti-TBM antibodies were
submitted to enzymatic treatment with DNAase;
0.2 ml of serum was mixed with 0.2 ml of barbital
buffered saline containing calcium and magnesium
and 50 Ll of DNAase (Deoxyribonuclease I, Worth-
ington Biochemical Corp., Freehold, N.J.) (0.5 mg/
ml) in the same buffer. After incubation at 37° C for
3 hours, 0.05 ml of 0.03 M EDTA was added to in-
hibit the DNAase activity. Controls were incubated
with barbital-buffered saline alone. The DNAase
treatment of the sera did not reduce their anti-TBM
activity (Table 7).
Third, IgG fractions were isolated from both sera
samples and were shown to contain a significant
anti-TBM binding activity. The latter was mainly di-
rected against the heteropolysaccharide-containing
glycopeptide isolated from TBM.
Reproducibility and sensitivity of the TBM radio-
immunoassay. The accuracy of the measurement of
rat antihuman TBM antibodies was determined by
calculating the CV of results of duplicate determina-
Ansitubular basement membrane antibody detection 603
Table 6. Influence of DNA-anti-DNA complexes on the percentage of labeled IBM Ag precipitated
Serum
Serum DNA-binding activitya, L
%
abeled TBM Ag precipitated
%
NHS
Anti-DNA antiserum
Anti-DNA antiserum + unlabeled DNA
6.9
41.6
12.8
76
6.1
8.2
Determined by the method of Fan [33].
Table 7. Effect of pretreatment with DNAase on the percentage
of labeled TBM Ag precipitated in sera from two patients
presenting with lupus nephritis
Pretreatment
Labeled TBM Ag precipitateda
%
DNAase 13,8
Controls' 14.6
Determined by radioimmunoassay; averages of the values
obtained with the two sera.
b Same dilution as pretreated samples, after incubation with
barbital buffered saline alone.
tions around their means [29]. In an assay in which
the final dilution of anti-TBM antibody was 10,
the CV was 9.81, calculated on the basis of values
ranging between 58 and 32% obtained from nine
samples. The reproducibility of the radioimmunoas-
say is therefore quite comparable to that reported
for other radioimmunoassay systems [34].
The sensitivity of the radioimmunoassay was
evaluated by correlating the anti-TBM antibody ti-
ters obtained using this technique with those ob-
tained by indirect immunolluorescence. The four
sera samples exhibiting anti-TBM antibodies in the
radioimmunoassay all demonstrated the presence of
anti-TBM antibodies by indirect immunofluores-
cence. The mean anti-TBM antibody titer obtained
with the former method, however, was five times
higher than that obtained with the latter.
Discussion
All basement membranes studied so far are most-
ly composed of glycoproteins [35, 36] containing
two major oligosaccharide chains: one is a disac-
charide formed of glucose and galactose, and the
other is a heteropolysaceharide composed of man-
nose, fucose, galactose, sialic acid, and hexos-
amines [18, 37]. It is not definitely known whether
the disaccharide and the heteropolysaccharide units
of basement membranes are linked to the same
polypeptide chain or whether they are present in
different polypeptide chains. Basement membranes
carry, however, at least three major antigenic com-
ponents as shown with limited proteolytic digestion
techniques [381: one of these components is the col-
lagen-like material with the disaccharide units, but
the other two, differing in their molecular weights,
contain the heteropolysaccharide units, and are
usually referred to as the "noncollagen-like" com-
ponents. The TBMs belong to the general category
of these structural glycoproteins, since they exhibit
significant amounts of 3- and 4-hydroxyproline, hy-
droxylysine, and since they contain both types of
oligosaccharide units described above [18]. Con-
trary to other basement membranes, however, the
TBMs isolated from human kidneys are associated
with interstitial collagen, as demonstrated by elec-
tron microscopy [17]. For this reason, collagenase
was chosen as a means of solubilizing the starting
insoluble TBM. This collagenase digestion could
explain why the soluble TBM antigens used con-
tained less collagenous polypeptides and more non-
collagenous polypeptides than did GBM antigens
[14]. The molecular weight fraction of 70,000 dal-
tons that we selected for the immunologic studies
does not necessarily represent an intact structural
subunit of the whole TBM; it may result from the
cleavage of one or more covalent bonds. These anti-
gens, however, still carry some of the major anti-
genic determinants of the whole TBM structure,
since, when injected into normal rats, they can in-
duce an interstitial nephritis with linear deposits
along the TBM only.
In this work, a synthetic polymer, polyethylene
glycol, has been used in a direct binding test for the
detection of circulating anti-TBM antibodies; the
addition of this polymer to the reaction medium is
used to exclude from the solvent most of the immu-
noglobulin molecules and the TBM antigens bound
to immunoglobulins, whereas these antigens them-
selves remain soluble in their free form [30]. The
principle of the PEG technique is therefore similar
to that used for the antigen binding test previously
described by Farr [33]. The Farr technique could
not be applied to the detection of anti-TBM anti-
bodies, since the selected TBM antigens are in-
soluble in 50% saturated ammonium sulfate
(Mahieu and Graindorge, unpublished data). Since
titration curves of antibodies to other antigens, such
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as bovine serum albumin, as demonstrated with the
PEG technique, are quite comparable to those ob-
tained by precipitation with 50% saturated am-
monium sulfate [30], it may be assumed that the
20% PEG solution precipitates most of the immuno-
globulin-bound antigens.
In the presence of NHS or NRS diluted 20 times,
the percentage of labeled TBM antigens precipi-
tated by the 20% PEG solution is lower than 10%. It
is therefore likely that the TBM antigens do not
bind nonspecifically to normal serum macromole-
cules. The specificity of this direct binding test has
been further demonstrated by the absence of signifi-
cant precipitation of the selected TBM antigens in
presence of rabbit antiwhole human serum, thus in-
dicating that these antigens are not contaminated by
normal serum proteins. Moreover, the cross-reac-
tivity of the labeled TBM antigens with GBM anti-
gens and with other collagen-like glycoproteins has
been studied. In presence of a 100-fold antigen ex-
cess, and using the anti-TBM antibodies found in
the serum of the two patients presenting with an in-
terstitial nephritis and linear deposits along the
TBM only, GBM antigens, Clq, and procollagen do
not inhibit the specific precipitation of IBM-Ag-
anti-TBM-Ab complexes by the 20% PEG solution.
Since the selected TBM antigens are mostly com-
posed of noncollagenous polypeptides, and since
the antitype IV collagen antibodies do not signifi-
cantly react in the radioimmunoassay with these an-
tigens, it seems reasonable to suggest that the IBM-
specific antigenic determinants belong to the non-
collagenous material of the TBM. The specificity of
the anti-IBM antibodies has been further investi-
gated using the disaccharide- or the heteropolysac-
charide-containing glycopeptides isolated from hu-
man IBM and GBM. We found that only the heter-
opolysaccharide-containing glycopepticle purified
from IBM strongly inhibits the binding of anti-TBM
antibodies with TBM antigens. This result is there-
fore in complete agreement with the above-men-
tioned interpretation.
Using the radioimmunoassay described herein,
we found that 9 of 11 patients presenting with gb-
merulonephritis and linear deposits of immunoglob-
ulins along the GBM exhibited significant anti-IBM
activity in their sera samples. Nonspecific binding
of labeled IBM antigens on molecules other than
immunoglobulins is unlikely to occur, since IgG
fractions purified from some positive sera bind
amounts of labeled IBM antigens similar to those
bound by the corresponding sera, Among these pos-
itive patients, 8 also displayed linear deposits of lgG
along the IBM. Of the 3 patients with anti-GBM
antibodies but without linear IgG IBM staining, the
sera samples of 2 did not exhibit any anti-IBM ac-
tivity. This supports the contention that the present
assay is specific for IBM antigens. Studies of the
reactivities of anti-GBM and anti-IBM antibodies
found in patients presenting with GN and linear IgG
GBM and IBM deposits are of interest. Indeed, the
anti-IBM antibodies are mainly directed against the
heteropolysaccharide-containing glycopeptide of
IBM, but the anti-GBM antibodies are mainly di-
rected against the disaccharide-containing glyco-
peptides isolated from IBM and GBM. Antibodies
directed against the "collagen-like" material of
basement membranes have been detected in the
sera samples of some patients presenting with rap-
idly progressive GN [14, 39]. Our results are there-
fore in agreement with those reported by other in-
vestigators [40] using antibodies eluted from the
kidneys of a patient presenting with a Good-
pasture's syndrome. Other studies [15, 41, 42] sug-
gested that the anti-GBM antibodies are mostly di-
rected against the noncollagenous polypeptides of
the membrane. Ihe reasons for these discrepancies
remain unknown. From our data, however, it
seems reasonable to suggest that the collagenous
polypeptides of human TBM carry the antigenic
determinants responsible for the cross-reactivity
between GBM and IBM, whereas the noncollage-
nous polypeptides carry the IBM-specific antigens.
Similar results about the specificity of autoanti-
bodies to IBM and GBM have been recently re-
ported after immunization of guinea pigs with vari-
ous renal basement membranes [43].
The existence of circulating anti-IBM antibodies
in two patients presenting with lupus nephritis is not
surprising, since anti-IBM antibodies have been
observed after immune complex gbomerular dis-
eases [8, 9]. A nonspecific binding of labeled IBM
Ag with free circulating DNA, or with DNA-anti-
DNA complexes has been excluded. Furthermore,
IgG fractions purified from these sera samples con-
tain a significant anti-TBM binding activity, mainly
directed against the heteropolysaccharide-contain-
ing glycopeptide isolated from IBM. Ihe absence
of linear IBM deposits by immunofluorescence mi-
croscopy could result from the examination of bad-
ly scarred kidneys. The absence of anti-IBM anti-
bodies by indirect immunofluorescence in these
sera could reflect differences of sensitivity between
the two methods, as the sensitivity of the radioim-
munoassay is five times higher than that of the in-
direct immunofluorescence technique.
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It is difficult hitherto to appreciate to what extent
the anti-TBM antibodies contribute to the severity
of the renal disease. In lupus nephritis, the presence
of granular IgG deposits and the low concentration
of anti-TBM antibodies do not suggest that such
antibodies play a major part in the pathogenesis of
the renal tubular lesions. The anti-TBM antibodies
detected in the sera samples of these patients might
represent an immune response to TBM antigens
that are released in the circulation secondarily to
the immune-complex-mediated tubular injury [44].
In glomerulonephritis, the glomerular lesions usual-
ly appeared severe enough to explain the renal in-
sufficiency. In some patients, however, presenting
with either a GN and linear IgG TBM and GBM de-
posits, or an interstitial nephritis and linear IgG
TBM deposits, the anti-TBM antibody levels were
very high, and severe tubular damage and inter-
stitial fibrosis were obvious. In these cases, it seems
reasonable to suggest that the anti-TBM antibodies
might have potentiated the tubular disease, as in the
two patients presenting with a Fanconi's syndrome.
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